Literature DB >> 30370501

Coronary arterial vasculature in the pathophysiology of hypertrophic cardiomyopathy.

Richard J Marszalek1,2,3, R John Solaro1,2,3, Beata M Wolska1,4.   

Abstract

Alterations in the coronary vascular system are likely associated with a mismatch between energy demand and energy supply and critical in triggering the cascade of events that leads to symptomatic hypertrophic cardiomyopathy. Targeting the early events, particularly vascular remodeling, may be a key approach to developing effective treatments. Improvement in our understanding of hypertrophic cardiomyopathy began with the results of early biophysical studies, proceeded to genetic analyses pinpointing the mutational origin, and now pertains to imaging of the metabolic and flow-related consequences of such mutations. Microvascular dysfunction has been an ongoing hot topic in the imaging of genetic cardiomyopathies marked by its histologically significant remodeling and has proven to be a powerful asset in determining prognosis for these patients as well as enlightening scientists on a potential pathophysiological cascade that may begin early during the developmental process. Here, we discuss questions that continue to remain on the mechanistic processes leading to microvascular dysfunction, its correlation to the morphological changes in the vessels, and its contribution to disease progression.

Entities:  

Keywords:  Energetics; Hypertrophic cardiomyopathy; Ischemia; Microvascular; Pathogenesis

Mesh:

Substances:

Year:  2018        PMID: 30370501      PMCID: PMC6481925          DOI: 10.1007/s00424-018-2224-y

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  139 in total

1.  Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations.

Authors:  Iacopo Olivotto; Francesca Girolami; Roberto Sciagrà; Michael J Ackerman; Barbara Sotgia; J Martijn Bos; Stefano Nistri; Aurelio Sgalambro; Camilla Grifoni; Francesca Torricelli; Paolo G Camici; Franco Cecchi
Journal:  J Am Coll Cardiol       Date:  2011-08-16       Impact factor: 24.094

Review 2.  Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis.

Authors:  Iacopo Olivotto; Franco Cecchi; Corrado Poggesi; Magdi H Yacoub
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

3.  A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.

Authors:  Eric M Green; Hiroko Wakimoto; Robert L Anderson; Marc J Evanchik; Joshua M Gorham; Brooke C Harrison; Marcus Henze; Raja Kawas; Johan D Oslob; Hector M Rodriguez; Yonghong Song; William Wan; Leslie A Leinwand; James A Spudich; Robert S McDowell; J G Seidman; Christine E Seidman
Journal:  Science       Date:  2016-02-05       Impact factor: 47.728

Review 4.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 5.  The paradox of adrenergic coronary vasoconstriction.

Authors:  E O Feigl
Journal:  Circulation       Date:  1987-10       Impact factor: 29.690

Review 6.  Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Julian O M Ormerod; Michael P Frenneaux; Mark V Sherrid
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

7.  Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein.

Authors:  Robert D Gaffin; James R Peña; Marco S L Alves; Fernando A L Dias; Shamim A K Chowdhury; Lynley S Heinrich; Paul H Goldspink; Evangelia G Kranias; David F Wieczorek; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2011-08-05       Impact factor: 5.000

8.  Irreversible triggers for hypertrophic cardiomyopathy are established in the early postnatal period.

Authors:  Leah Cannon; Ze-Yan Yu; Tadeusz Marciniec; Ashley J Waardenberg; Siiri E Iismaa; Vesna Nikolova-Krstevski; Elysia Neist; Monique Ohanian; Min Ru Qiu; Stephen Rainer; Richard P Harvey; Michael P Feneley; Robert M Graham; Diane Fatkin
Journal:  J Am Coll Cardiol       Date:  2015-02-17       Impact factor: 24.094

Review 9.  Calcium and the failing heart: phospholamban, good guy or bad guy?

Authors:  Robert H G Schwinger; Konrad F Frank
Journal:  Sci STKE       Date:  2003-04-29

10.  Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Nancy K Sweitzer; Barbara McDonough; Barry J Maron; Susan A Casey; J G Seidman; Christine E Seidman; Scott D Solomon
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

View more
  7 in total

Review 1.  A Perspective on Personalized Therapies in Hypertrophic Cardiomyopathy.

Authors:  Paul H Goldspink; Chad M Warren; Jan Kitajewski; Beata M Wolska; R John Solaro
Journal:  J Cardiovasc Pharmacol       Date:  2021-03-01       Impact factor: 3.271

2.  Angiotensin II inhibits apoptosis of mouse aortic smooth muscle cells through regulating the circNRG-1/miR-193b-5p/NRG-1 axis.

Authors:  Yan Sun; Suli Zhang; Mingming Yue; Yang Li; Jing Bi; Huirong Liu
Journal:  Cell Death Dis       Date:  2019-05-01       Impact factor: 8.469

Review 3.  Implications of the complex biology and micro-environment of cardiac sarcomeres in the use of high affinity troponin antibodies as serum biomarkers for cardiac disorders.

Authors:  Christopher R Solaro; R John Solaro
Journal:  J Mol Cell Cardiol       Date:  2020-05-19       Impact factor: 5.000

4.  Dysfunctional Network and Mutation Genes of Hypertrophic Cardiomyopathy.

Authors:  Yunwen Cui; Cheng Liu; Jian Luo; Jie Liang
Journal:  J Healthc Eng       Date:  2022-01-28       Impact factor: 2.682

5.  Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathy.

Authors:  Paola Roldan; Sriram Ravi; James Hodovan; J Todd Belcik; Stephen B Heitner; Ahmad Masri; Jonathan R Lindner
Journal:  Cardiovasc Ultrasound       Date:  2022-09-19       Impact factor: 2.263

Review 6.  The potential roles of Von Willebrand factor and neutrophil extracellular traps in the natural history of hypertrophic and hypertensive cardiomyopathy.

Authors:  Richard C Becker; A Phillip Owens; Sakthivel Sadayappan
Journal:  Thromb Res       Date:  2020-05-07       Impact factor: 3.944

7.  Phenotyping hypertrophic cardiomyopathy using cardiac diffusion magnetic resonance imaging: the relationship between microvascular dysfunction and microstructural changes.

Authors:  Arka Das; Christopher Kelly; Irvin Teh; Christopher Nguyen; Louise A E Brown; Amrit Chowdhary; Nicholas Jex; Sharmaine Thirunavukarasu; Noor Sharrack; Miroslawa Gorecka; Peter P Swoboda; John P Greenwood; Peter Kellman; James C Moon; Rhodri H Davies; Luis R Lopes; George Joy; Sven Plein; Jürgen E Schneider; Erica Dall'Armellina
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-02-22       Impact factor: 6.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.